TrialESMO open2025

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

A R Filippi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.